GAMMA Investing LLC Has $403,000 Stock Holdings in Astrana Health, Inc. (NASDAQ:ASTH)

GAMMA Investing LLC increased its stake in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 5,794.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,497 shares of the company's stock after purchasing an additional 12,285 shares during the quarter. GAMMA Investing LLC's holdings in Astrana Health were worth $403,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ASTH. 325 Capital LLC increased its position in Astrana Health by 30.3% during the 4th quarter. 325 Capital LLC now owns 886,916 shares of the company's stock worth $27,964,000 after purchasing an additional 206,009 shares in the last quarter. Renaissance Technologies LLC increased its position in Astrana Health by 217.6% during the 4th quarter. Renaissance Technologies LLC now owns 217,900 shares of the company's stock worth $6,870,000 after purchasing an additional 149,300 shares in the last quarter. Royce & Associates LP increased its position in Astrana Health by 122.3% during the 4th quarter. Royce & Associates LP now owns 255,552 shares of the company's stock worth $8,058,000 after purchasing an additional 140,584 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Astrana Health by 10.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,045,540 shares of the company's stock worth $32,968,000 after purchasing an additional 101,192 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Astrana Health by 136.1% during the 4th quarter. JPMorgan Chase & Co. now owns 163,532 shares of the company's stock worth $5,156,000 after purchasing an additional 94,268 shares in the last quarter. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Astrana Health Trading Down 1.6%

NASDAQ:ASTH opened at $24.26 on Friday. The firm's fifty day moving average is $28.13 and its 200-day moving average is $31.87. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.70 and a current ratio of 1.70. Astrana Health, Inc. has a 52 week low of $23.12 and a 52 week high of $63.20. The firm has a market cap of $1.36 billion, a P/E ratio of 33.69, a P/E/G ratio of 1.30 and a beta of 0.85.

Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.23 by ($0.09). Astrana Health had a net margin of 1.56% and a return on equity of 4.90%. The firm had revenue of $620.39 million during the quarter, compared to the consensus estimate of $628.11 million. During the same period in the prior year, the company posted $0.31 earnings per share. The company's revenue for the quarter was up 53.4% compared to the same quarter last year. Equities analysts expect that Astrana Health, Inc. will post 1.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Robert W. Baird lowered their price objective on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. Barclays assumed coverage on shares of Astrana Health in a research report on Tuesday, April 1st. They set an "equal weight" rating and a $36.00 price objective for the company. Bank of America reduced their target price on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Stifel Nicolaus reduced their target price on shares of Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Finally, Truist Financial reduced their target price on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating on the stock in a report on Tuesday, March 18th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $53.29.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.

Want to see what other hedge funds are holding ASTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrana Health, Inc. (NASDAQ:ASTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.